Riskpilot← Back to searchSign inGet full accessPharmor AB
ABActiveOrg 5569849754Ellahagsvägen 17Business and other management consultancy activities · NACE 7020Est. 20141 employees
Revenue 2025
SEK 2,4M
-17% vs 2024
EBITDA margin
30.3%
-46% vs 2024
Equity ratio
54.7%
Financial strength
Net profit 2025
SEK 189K
-82% vs 2024
| Revenue | SEK 2,4M | -17% |
| EBITDA | SEK 713K | -46% |
| Net profit | SEK 189K | -82% |
| Total assets | SEK 6,6M | -3% |
| Equity | SEK 3,6M | -1% |
| Employees | 1 | — |
Legal name
Pharmor AB
Org number
5569849754
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
2 oktober 2014
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva förvaltning av aktier och fastigheter, styrelseuppdrag och konsultverksamhet inom Life Science-området, förvaltning av immateriella tillgångar samt därmed förenlig verksamhet.
Address
Ellahagsvägen 17
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 796 | 2 980 | 3 682 | 2 833 | 2 353 |
| Staff expenses | — | −1 025 | −1 132 | −1 126 | −1 179 |
| EBITDA | 1 321 | 1 300 | 1 641 | 1 312 | 713 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 1 321 | 1 300 | 1 641 | 1 312 | 713 |
| Net financials | −810 | −376 | −36 | 163 | −327 |
| Profit before tax | 690 | 697 | 1 272 | 1 293 | 356 |
| Tax | −250 | −229 | −289 | −267 | −167 |
| Net profit | 440 | 468 | 984 | 1 026 | 189 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 793 | 4 561 | 5 784 | 6 824 | 6 625 |
| Equity | 1 751 | 2 031 | 2 820 | 3 642 | 3 621 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 653 | 914 | 1 015 | 1 051 | 842 |
| Total debt | 653 | 914 | 1 015 | 1 051 | 842 |
EBITDA margin
30.3%
This company
15.8%
Market median
+92% vs market
20212025
Equity ratio
54.7%
This company
38.2%
Market median
+43% vs market
20212025
Return on equity
5.2%
This company
18.4%
Market median
-72% vs market
20212025
Net profit margin
8.0%
This company
8.1%
Market median
-1% vs market
20212025
Asset turnover
0.36×
This company
1.12×
Market median
-68% vs market
20212025
Debt / equity
0.83×
This company
0.62×
Market median
+34% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharmor AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Elisabet Murby | Deputy Board Member | 0 companies |
| Sten Gunnar Otto Skolling | Board of Directors | 0 companies |